During their virtual meeting on Monday, the Vaccine and Antiviral Prioritization Policy Committee (VAPPC) members discussed the latest developments with the Pfizer-BioNTech vaccine and trials with individuals 12-15 years of age.
Discussions on expanding age eligibility, however, were tabled pending approval from both the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).
The VAPPC was also updated on Guam’s COVID-19 vaccine allotment for April. Over the weekend, Guam received a total of 53,170 doses of the COVID-19 vaccine.
The Department of Public Health and Social Services’ (DPHSS) Immunization Program received 25,740 doses of the Pfizer-BioNTech vaccines, 15,000 Moderna, and 1,300 Johnson & Johnson/Janssen (J&J/Janssen).
Additionally, Guam’s Northern Region Community Health Center received 5,850 Pfizer-BioNTech, 500 Moderna, 100 J&J/Janssen doses. The Southern Region Community Health Center also received a total of 4,680 Pfizer-BioNTech doses.